Administrative Supplements to Grants and Cooperative Agreements (March 16)
Administrative supplements are funds awarded above study section-recommended levels or outside the fiscal year funding policies. NIAID provides these funds for administrative purposes, and we generally pay only for items resulting from events unforeseen when the competing application was submitted.
| Program Title | Administrative Supplements to Grants and Cooperative Agreements (March 16) |
|---|---|
| Funding Agency | NIH |
| Website | http://www.niaid.nih.gov/ncn/sop/adminsupp.htm |
| Due Date | Nov 23, 2009 06:02 PM |
http://www.niaid.nih.gov/ncn/sop/adminsupp.htmhttp://www.niaid.nih.gov/ncn/sop/adminsupp.htm
The purpose of this procedure is to enable NIAID to add funds to a grant or cooperative agreement for defined purposes that do not significantly expand a project's scope.
NIAID awards administrative supplements to do the following:
- Reinstate grant funds that were approved by the scientific review group but cut due to NIAID’s 20 percent cap on renewal applications (first year only).
- Reinstate scientific review group reductions of budget, time, or both. This can be done during any year of a grant except the last. A specific aim can be reinstated, but only with Council approval.
- Support an unanticipated increase in approved direct costs, including items thought to be available at the time of award that later became unavailable to a PI. Examples include increases in animal costs and loss of equipment identified in an application.
- Use or preserve a unique research material or resource that may otherwise be lost. Example: maintaining a unique knockout mouse model.
- Add patients, populations, or other items related to a protocol -- such as items related to safety issues or data and safety monitoring boards (DSMB) needs -- due to enrollment issues, a need for statistically significant data, or responses to protocol and DSMB reviews. NIAID can supplement a grant to obviate threats to patients in a clinical trial by addressing issues in an FDA clinical hold for an investigational new drug application or investigational device exemption.
- Provide an orderly termination or temporary continuation of support to prevent loss of research resources or hardship of personnel, which includes taking advantage of a rare event with an immediate need, e.g., salvaging a rare animal model.
- Address special time-critical cases such as countering a major threat to public health, e.g., creating smallpox vaccines to counter a bioterrorism threat or developing the capacity to respond to a new epidemic, such as West Nile virus.
- Natural disasters.
